JACC: CardioOncology Pulse - Clinical Risk Mitigation, Pathophysiology, and Genetics of Anthracycline-Associated Cardiomyopathy

Release Date:

Aarti Asnani, MD discusses anthracyline-induced cardiomyopathy, including risk mitigation strategies, underlying pathogenesis, genetic variants associated with increased risk of this adverse event, and gaps in our understanding. Moderated by Sarah Waliany, MD, MS.

JACC: CardioOncology Pulse - Clinical Risk Mitigation, Pathophysiology, and Genetics of Anthracycline-Associated Cardiomyopathy

Title
JACC: CardioOncology Pulse - Clinical Risk Mitigation, Pathophysiology, and Genetics of Anthracycline-Associated Cardiomyopathy
Copyright
Release Date

flashback